THTX - Theratechnologies to Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology™ Platform | Benzinga
- Study to assess new camptothecin-peptide conjugates for the treatment of sortilin-positive colorectal cancers
- Separate data to highlight activity of sudocetaxel zendusortide (TH1902) to trigger the cGAS/STING pathway potentiate and anti-PD-L1 immunotherapy tumor cell killing
MONTREAL, March 28, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced two posters will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2024, demonstrating the potential of its SORT1+ Technology™ platform – including novel camptothecin-peptide conjugates and its lead investigational peptide drug conjugate (PDC) candidate, sudocetaxel zendusortide (TH1902), as anticancer treatments. The AACR meeting is taking place April 5-10 in San Diego, CA.
These preclinical presentations reinforce existing data for sudocetaxel zendusortide to activate anti-PD-L1 immunotherapy tumor cell killing in SORT+1 cancers and provide the first evidence for novel camptothecin-peptide conjugates in the treatment of SORT+1 colorectal cancers.
"The studies we are presenting at the AACR 2024 meeting highlight the significant advancements made on our SORT+1 Technology™ platform through careful assessment of investigational compounds, including sudocetaxel zendusortide, which is currently being evaluated in a Phase 1 trial in patients with advanced ovarian cancer," said Christian Marsolais, Ph.D., Senior Vice President and Chief Medical Officer of Theratechnologies. "These data showcase the potential of our PDC candidates with different payloads as potential future treatment options for a broad range of cancer types."
Theratechnologies will present the following data at AACR 2024:
Monday April 8, 2024: 9:00am-12:30pm Pacific Time (PT)
- Presenting Author: Sanjoy Kumar Das, Ph.D., Theratechnologies
- Session Category: Experimental and Molecular Therapeutics
- Session Title: New Technologies
- Location: Poster Section 28
- Poster Board Number: 28
- Abstract Presentation Number: 2071
Monday April 8, 2024: 1:30pm- 5:00pm Pacific Time (PT)
Title: Sudocetaxel Zendusortide (TH1902) triggers the cGAS/STING pathway and ...